Javascript must be enabled to continue!
Human herpesvirus 6B U19 protein is a PML-regulated transcriptional activator that localizes to nuclear foci in a PML-independent manner
View through CrossRef
Human herpesvirus 6B (HHV-6B) contains anIE-Bdomain spanning open reading framesU16/17–U19, based on homology with human cytomegalovirus. Here, the protein product, U19, of the HHV-6BU19gene is identified as a 47 kDa transcriptional activator. HHV-6B infection or overexpression of U19 transactivated the RANTES promoter. Mutational analysis of the promoter indicated that transactivation was not critically dependent on the promoter sites CRE, NF-κB, ISRE or NF-IL6. ND10 are nuclear substructures that are involved in several cellular regulatory pathways, including those controlling gene expression. HHV-6B infection resulted in a reduced number of ND10 structures, but with a concomitantly increased level of promyelocytic leukaemia (PML) protein expression and mRNA induction. The U19 protein co-located to ND10 with PML and heterochromatin protein 1 (HP1), but whilst PML formed a ring structure, U19 also localized to the centre of ND10. Knockdown of PML by small interfering RNA did not prevent U19 localization to ND10-like foci, but instead led to a fourfold increase in U19-induced transcription from the RANTES promoter. Generation of four truncated U19 proteins indicated that the N-terminal portion of the protein contains a sequence responsible for nuclear localization; a domain in the N-terminal half of U19 is responsible for its ND10 localization, whereas the C-terminal portion contains the transactivation domain. None of the truncated proteins retained full transactivating ability on the RANTES promoter. Thus, U19 is a transcriptional activator that co-localizes with PML and localizes to ND10-like foci independently of PML, yet is regulated negatively by PML or its associated proteins.
Microbiology Society
Title: Human herpesvirus 6B U19 protein is a PML-regulated transcriptional activator that localizes to nuclear foci in a PML-independent manner
Description:
Human herpesvirus 6B (HHV-6B) contains anIE-Bdomain spanning open reading framesU16/17–U19, based on homology with human cytomegalovirus.
Here, the protein product, U19, of the HHV-6BU19gene is identified as a 47 kDa transcriptional activator.
HHV-6B infection or overexpression of U19 transactivated the RANTES promoter.
Mutational analysis of the promoter indicated that transactivation was not critically dependent on the promoter sites CRE, NF-κB, ISRE or NF-IL6.
ND10 are nuclear substructures that are involved in several cellular regulatory pathways, including those controlling gene expression.
HHV-6B infection resulted in a reduced number of ND10 structures, but with a concomitantly increased level of promyelocytic leukaemia (PML) protein expression and mRNA induction.
The U19 protein co-located to ND10 with PML and heterochromatin protein 1 (HP1), but whilst PML formed a ring structure, U19 also localized to the centre of ND10.
Knockdown of PML by small interfering RNA did not prevent U19 localization to ND10-like foci, but instead led to a fourfold increase in U19-induced transcription from the RANTES promoter.
Generation of four truncated U19 proteins indicated that the N-terminal portion of the protein contains a sequence responsible for nuclear localization; a domain in the N-terminal half of U19 is responsible for its ND10 localization, whereas the C-terminal portion contains the transactivation domain.
None of the truncated proteins retained full transactivating ability on the RANTES promoter.
Thus, U19 is a transcriptional activator that co-localizes with PML and localizes to ND10-like foci independently of PML, yet is regulated negatively by PML or its associated proteins.
Related Results
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
<div>Abstract<p>Promyelocytic leukemia (<i>PML</i>) has been implicated in a variety of functions, including control of TP53 function and modulation of cell...
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
<div>Abstract<p>Promyelocytic leukemia (<i>PML</i>) has been implicated in a variety of functions, including control of TP53 function and modulation of cell...
Rotavirus NSP1 localizes in the nucleus to disrupt PML nuclear bodies during infection
Rotavirus NSP1 localizes in the nucleus to disrupt PML nuclear bodies during infection
ABSTRACT
The rotavirus nonstructural protein 1 (NSP1) antagonizes interferon (IFN) induction in infected host cells. The primary function of NSP1 is thought to be d...
Rôle différentiel des isoformes de PML en réponse au trioxyde d’arsenic et dans la défense antivirale
Rôle différentiel des isoformes de PML en réponse au trioxyde d’arsenic et dans la défense antivirale
Les interférons (IFN) constituent une famille de cytokines aux propriétés antiprolifératives et antivirales. Ils activent, via la voie Jak/STAT, des gènes spécifiques dont les prod...
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes
Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes
ABSTRACT
Promyelocytic leukemia (PML) nuclear bodies (PML-NBs), a class of membrane-less cellular organelles, participate in various biological activities. PML-NBs a...
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Background
Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. Cancer cells that use the ALT pathway exhibit dist...

